[Federal Register Volume 63, Number 102 (Thursday, May 28, 1998)]
[Notices]
[Pages 29235-29236]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-14139]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Noncompetitive
Antagonists of Dopamine Reuptake Inhibitors To Treat Drug Addiction
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
PCT Application Serial No. PCT/US97/19758, entitled, ``Sustained
Release Derivatives of Hydroxylated Analogs of Substituted 1-(2-
[Bis(aryl)methoxy]ethyl)-piperazines and -homopiperazines and Their Use
as
[[Page 29236]]
Noncompetitive Antagonists of Dopamine Reuptake Inhibitors'', based on
U.S. Provisional Patent Application Serial No. 60/030,248, filed
October 31, 1996, to Trillium Neuroscience Inc., having a place of
business in Washington, DC. The patent rights in this invention have
been assigned to the United States of America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before July 27,
1998 will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Leopold J. Luberecki, Jr., J.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD
20852-3804; Telephone: (301) 496-7735, ext. 223; Facsimile: (301) 402-
0200.
SUPPLEMENTARY INFORMATION: In an effort to develop an efficacious
treatment for cocaine addiction, this invention describes sustained-
release derivatives of hydroxylated analogs of substituted 1-(2-
[bis(aryl)methoxy]ethyl)-piperazines and -homopiperazines. These
compounds bind to the dopamine transporter but do not inhibit dopamine
reuptake, thereby providing a sustained increase in the level of
extracellular dopamine and providing the drug abuser with some relief
from drug craving due to dopamine deficiency, yet they simultaneously
inhibit cocaine from further elevating the level of extracellular
dopamine and increasing the probability of additional toxic side
effects. The invention provides the sustained-release derivatives,
pharmaceutical compositions comprising the same, and a method of using
such sustained released derivatives as a treatment for cocaine
addiction.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to the use of the invention for the
development of pharmaceutical compounds to treat drug addiction.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 18, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-14139 Filed 5-27-98; 8:45 am]
BILLING CODE 4140-01-M
